ALLIANCE PHARMA PLC

AGM Information • May 25, 2023

National Storage Mechanism | Additional information

RNS Number : 6880A

Alliance Pharma PLC

25 May 2023

For immediate release	25 May 2023

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Result of AGM

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, at its Annual General Meeting held earlier today, all the resolutions, as set out in the Notice of Meeting, were duly passed on a poll.

The number of the Group's shares in issue as at the date of the meeting was 540,124,673 ordinary shares of 1p each.

The votes were as follows:

RESOLUTION		VOTES FOR	%	VOTES AGAINST	%	VOTES WITHHELD*
1	Report and Accounts	219,104,625	80.85	51,908,041	19.15	101,986,122
2	Final dividend	233,018,515	62.48	139,907,211	37.52	73,062
3	Elect J. Heper	264,206,888	92.73	20,714,828	7.27	88,077,072
4	Elect M. Sutherland	233,010,074	81.78	51,908,621	18.22	88,080,093
5	Re-elect P. Butterfield	222,069,893	77.94	62,848,802	22.06	88,080,093
6	Re-elect A. Franklin	264,044,516	92.67	20,874,179	7.33	88,080,093
7	Re-elect R. Jones	201,039,250	70.56	83,879,445	29.44	88,080,093
8	Re-elect J. LeCouilliard	206,081,209	77.31	60,470,644	22.69	106,446,935
9	Re-elect K. Neirynck	253,533,764	88.98	31,387,952	11.02	88,077,072
10	Appoint Auditor	284,909,887	99.99	7,118	0.01	88,081,783
11	Remuneration of Auditor	284,912,231	99.99	4,328	0.01	88,082,229
12	Allot shares - general	179,118, 371	62.87	105,800,885	37.13	88,079,532
13	Allot shares - additional	178,986,132	62.82	105,933,124	37.18	88,079,532
14	Disapply pre-emption rights - general	228,436,470	80.18	56,483,517	19.82	88,078,801
15	Disapply pre-emption rights - additional	228,318,841	80.13	56,601,146	19.87	88,078,801

The Board notes the votes against Resolutions 2, 5, 7, 8, 12 and 13 and will consult with shareholders to understand their views and publish the results of that consultation in due course.

Chris Chrysanthou

Group General Counsel & Company Secretary

25 May 2023

*Each share carries one vote and a 'vote withheld' is not a vote in law and has not been counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the 'votes for' total.

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications	+ 44 (0)1249 705168
ir@allianceph.com
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited (Nominated Adviser and Corporate Broking)	+ 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc	+ 44 (0)20 7597 5970
Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSEEFFIEDSELI